Almirall S.A. stock faces pipeline pressure amid European pharma shifts

Almirall S.A. (ISIN: ES0157097017) reports mixed Q4 results with skincare growth offsetting respiratory setbacks. Shares on Bolsa de Madrid dipped 2.1% to €10.85 amid broader sector rotation. DACH investors eye dividend stability and M&A potential in undervalued Spanish pharma.

Almirall S.A., the Barcelona-based specialty pharmaceutical company, released its full-year 2025 results on March 18, 2026, revealing a 4.2% revenue increase to €1.19 billion. Growth was driven by strong performances in its dermatology franchise, particularly Ebglyss for atopic dermatitis, which posted 28% year-over-year sales growth. However, the stock fell 2.1% to €10.85 on the Bolsa de Madrid in EUR terms on March 19, reflecting investor concerns over pipeline delays in respiratory drugs and rising R&D costs. For DACH investors, this presents a value play in a sector facing patent cliffs elsewhere, with Almirall's 5.2% dividend yield offering stability amid ECB rate cut expectations.

As of: 20.03.2026

By Dr. Elena Voss, Senior Pharma Equity Analyst – Tracking European mid-caps where innovation meets undervaluation in the post-patent era.

Core Business Delivers Amid Headwinds

Almirall's core dermatology segment generated €692 million in 2025 revenues, up 7.8% from prior year. Ebglyss, launched in Europe in 2024, reached blockbuster trajectory with €245 million in sales across key markets including Germany and Spain. Skincare brands like Silkis and Acnase contributed steady mid-single-digit growth, bolstered by expanded distribution in Central Europe.

The respiratory portfolio, however, stagnated at €312 million, pressured by generic competition to long-time seller aclidinium (Tudorza). Management highlighted pipeline progress with ALK-001 for psoriasis entering Phase III, but timelines slipped by six months due to enrollment challenges. This mix underscores Almirall's pivot from generics-vulnerable inhalers to high-margin biologics, a transition resonant for DACH portfolios heavy in Bayer and Roche.

EBITDA margins held at 28.4%, supported by disciplined cost controls despite 12% R&D hike to €210 million. Net debt stood at €180 million, yielding a comfortable leverage ratio of 0.9x EBITDA, positioning the firm for bolt-on acquisitions.

Pipeline Catalysts and Setbacks

Almirall's R&D engine targets immuno-dermatology, with Ebglyss label expansion into pediatrics under EMA review, potentially adding €150 million peak sales by 2028. ALM241, a next-gen JAK inhibitor for vitiligo, showed promising Phase IIb data in December 2025, with Phase III initiation slated for Q2 2026. These assets address unmet needs in chronic skin conditions affecting 20% of Europeans.

Respiratory remains a drag, with no near-term launches after the 2024 failure of ALN-003 in COPD trials. Management allocated €80 million to early-stage oncology assets via partnerships, diversifying beyond derm. Investors note the 18-month pipeline runway as shorter than peers like UCB, raising execution risks.

For pharma watchers, Almirall's 15% R&D-to-sales ratio lags Sanofi's 20%, but targeted spend yields higher Phase III success rates at 65% versus industry 50% average.

Financial Health and Shareholder Returns

Free cash flow rose 15% to €220 million, funding a proposed €0.62 annual dividend, payable in two tranches starting May 2026. Payout ratio of 55% balances growth investments, appealing to yield-seeking DACH funds amid low bundesbank rates. Buyback program of €50 million authorized, targeting 4% of float.

Balance sheet strength allows €300 million M&A firepower, with CEO Carlos Gallardo signaling interest in US dermatology assets. ROE of 12.4% trails sector median but improves from 9.2% in 2024, driven by asset turnover gains.

Compared to 2024, capex moderated to 4% of sales, prioritizing digital manufacturing upgrades in Spain and Switzerland facilities.

Market Reaction and Valuation

On Bolsa de Madrid, Almirall shares traded at €10.85, down 2.1% on March 19 volume of 450,000 shares versus 30-day average 380,000. Forward P/E of 11.2x versus European pharma 14.5x suggests undervaluation, with EV/EBITDA at 7.8x.

Analysts maintain Hold consensus, average target €12.50 implying 15% upside. JPMorgan cited pipeline delays as downgrade trigger from Overweight, while Kepler Cheuvreux upgraded on Ebglyss traction. Short interest below 1%, indicating limited bearish bets.

Stock underperforms IBEX 35 by 8% YTD, reflecting sector derating post-2025 biotech funding crunch.

Risks and Open Questions

Key vulnerability lies in Ebglyss competition from Lilly's Ebglyss rivals and Pfizer's atopic dermatitis entrants, potentially capping market share at 15% in EU. Regulatory hurdles for label expansions could delay revenue recognition into 2027.

Forex exposure, with 25% sales from US and UK, heightens EUR weakness risks despite natural hedges. Geopolitical tensions in supply chains threaten API sourcing from India, where 40% of actives originate.

Sustainability reporting flags Scope 3 emissions from clinical trials, with EU CSRD compliance costs estimated at €15 million annually. Board refresh post-AGM may introduce activist pressure on capital allocation.

DACH Investor Perspective

German-speaking investors hold 12% of Almirall's register, led by DWS and Union Investment stakes. Proximity to Barcelona facilitates site visits, while shared EMA regulatory framework eases pipeline tracking. Dividend timing aligns with Pfingsten payouts, complementing Allianz yields.

Spain's pharma sector benefits from NextGenEU funds, with Almirall securing €45 million for biotech hub expansion. DACH funds can leverage IBEX ETF exposure for low-cost entry, avoiding ADR premiums on US listings.

Macro tailwinds include aging demographics boosting derm demand, mirroring Merck KGaA trends. Risks center on Spanish fiscal policy shifts post-elections.

Strategic Outlook and Peer Context

Almirall targets 6-8% CAGR through 2028, front-loaded by Ebglyss ramp. M&A focus on Phase II assets could double pipeline depth, echoing Grifols' playbook. Partnerships with J&J and Sanofi de-risk late-stage development.

Versus peers, Almirall trades at discount to Leo Pharma's 13x P/E, justified by smaller scale but offset by 90% EU revenue concentration versus Leo's Nordics tilt. Long-term, biologics shift promises margin expansion to 32% by 2028.

ESG scores improved to AA from MSCI, driven by diversity initiatives and green chemistry adoption.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.